EUVIMEDEUVIMED entdecken
Vergleichsstudie

A pilot study of nectin-4-targeted radioligand [68Ga]Ga-FZNR-1 in patients with pancreatic ductal adenocarcinoma: head-to-head comparison with [18F]-FDG

Chunjuan Jiang, Miaoyan Wei, Panli Li, Silong Hu, Xiaoping Xu, Jindian Li, Dan Huang, Weiwei Weng, Xianjun Yu, Shaoli Song iD

European Journal of Nuclear Medicine and Molecular Imaging · 2026

DOI: 10.1007/s00259-025-07609-0 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Chunjuan Jiang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Key Program of National Natural Science Foundation of China, National Natural Science Foundation of China, Shanghai Scientific and Technological Innovation Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Nectin-4 is highly expressed in pancreatic cancer. Accurate and quantitative measurements of Nectin-4 is useful for tumor diagnosis, treatment selection, and prognostic assessment. This study aimed to evaluate the diagnostic efficacy of a Nectin-4-targeted radioligand [68Ga]Ga-FZNR-1 for pancreatic ductal adenocarcinoma. METHODS: Thirty-three patients with PDAC were recruited and underwent head-to-head [68Ga]Ga-FZNR-1 and [18F]-FDG PET/CT for initial staging or to detect recurrence and metastases. PET/CT findings were confirmed by histopathology or follow-up imaging. Thirteen primary and metastatic lesions from the 33 patients were evaluated for Nectin-4 immunohistochemical expression. RESULTS: [18F]-FDG and [68Ga]Ga-FZNR-1 PET/CT were comparable in detecting primary tumors, lymph node metastases, and distant metastases (96.00% [24/25] vs. 92.00% [23/25], 88.24% [15/17] vs. 82.35% [14/17], 95.24% [20/21] vs. 95.24% [20/21]). [68Ga]Ga-FZNR-1 PET/CT demonstrated slightly higher specificity and accuracy than [18F]-FDG PET/CT for distant metastases (100.00% vs. 93.75%, 100.00% vs. 96.97%). The receiver operating characteristic (ROC) curve revealed that [68Ga]Ga-FZNR-1 had high sensitivity and specificity in detecting Nectin-4-expressing lesions. Both SUVmax and TBR on [68Ga]Ga-FZNR-1 PET/CT were significantly and positively correlated with the expression of Nectin-4 (both r = 0.89, both p < 0.001). CONCLUSION: [68Ga]Ga-FZNR-1 is excellent in diagnosing primary, metastatic, and recurrent lesions of PDAC. In particular, it may be a useful complement in patients with distant metastases that cannot be detected by [18F]-FDG PET/CT. [68Ga]Ga-FZNR-1 PET/CT could quantify the Nectin-4 expression. Moreover, [68Ga]Ga-FZNR-1 PET/CT may have potential predictive value in the prognostic assessment of patients with PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fluorodeoxyglucose F18Positron Emission Tomography Computed TomographyCarcinoma, Pancreatic DuctalPancreatic NeoplasmsCell Adhesion MoleculesHumansMaleFemalePilot ProjectsMiddle AgedAgedGallium RadioisotopesAged, 80 and overRadiopharmaceuticalsAdultNectins

Substanzen

Fluorodeoxyglucose F18Cell Adhesion MoleculesGallium RadioisotopesNECTIN4 protein, humanRadiopharmaceuticalsGallium-68Nectins

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Department of Oncology, Medical College, Fudan University, Shanghai, China.
  • Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China.
  • Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, 200032, Shanghai, China.
  • Shanghai Pancreatic Cancer Institute, 200032, Shanghai, China.
  • Shanghai Key Laboratory of Precision Medicine for Pancreatic Cancer, 200032, Shanghai, China.

ORCID-Profile: Shaoli Song

Förderung

  • Key Program of National Natural Science Foundation of China
  • National Natural Science Foundation of China
  • Shanghai Scientific and Technological Innovation Program
  • Shanghai Anticancer Association Program
  • Shanghai Hospital Development Center

Zitieren

APA

Jiang, C., Wei, M., Li, P., Hu, S., Xu, X., Li, J., Huang, D., Weng, W., Yu, X., & Song, S. (2026). A pilot study of nectin-4-targeted radioligand [68Ga]Ga-FZNR-1 in patients with pancreatic ductal adenocarcinoma: head-to-head comparison with [18F]-FDG. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07609-0

Vancouver

Jiang C, Wei M, Li P, Hu S, Xu X, Li J, et al. A pilot study of nectin-4-targeted radioligand [68Ga]Ga-FZNR-1 in patients with pancreatic ductal adenocarcinoma: head-to-head comparison with [18F]-FDG. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-025-07609-0

BibTeX
@article{Jiang2026,
  author = {Jiang, Chunjuan and Wei, Miaoyan and Li, Panli and Hu, Silong and Xu, Xiaoping and Li, Jindian and Huang, Dan and Weng, Weiwei and Yu, Xianjun and Song, Shaoli},
  title = {A pilot study of nectin-4-targeted radioligand [68Ga]Ga-FZNR-1 in patients with pancreatic ductal adenocarcinoma: head-to-head comparison with [18F]-FDG},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  doi = {10.1007/s00259-025-07609-0}
}
Kostenlos starten →